Abstract
Lymph node status is the most important prognostic factor in melanoma. Because regional spread to lymph nodes can occur in 20% of those with melanoma, the sentinel lymph node (SLN) biopsy has become a staging tool for isolating and sampling the draining lymph node basin for metastatic spread [1–7]. Refinements in the use of radioactive tracers for lymphatic mapping and the use of intraoperative gamma probes have resulted in a greater than 96% success rate for SLN biopsy. Despite these advances, there is a 2% to 6% incidence of false-negative (FN) SLN biopsies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
